[Advances in thalidomide therapy for idiopathic myelofibrosis].

Abstract

Idiopathic myelofibrosis a Philadelphia-negative chronic myeloproliferative disorder. Potentially curative therapies, such as stem-cell transplantation, are reserved only for a minority of patients. Currently palliative therapies such as androgen and hydroxycarbamide are commonly used but with poor results. Thalidomide has anti-angiogenic effect and also can inhibit cytokines, and therefore plays a certain role in the treatment of a subset of idiopathic myelofibrosis.

• Authors: Li Song, Jia-Lin Chen
• Journal: Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae (Zhongguo Yi Xue Ke Xue Yuan Xue Bao) Vol. 31 Issue 5 Pg. 651-3 (Oct 2009) ISSN: 1000-503X [Print] China
• PMID: 19968089 (Publication Type: English Abstract, Journal Article, Review)

Chemical References

• Angiogenesis Inhibitors
• Immunosuppressive Agents
• Thalidomide

Topics

• Angiogenesis Inhibitors (adverse effects, therapeutic use)
• Humans
• Immunosuppressive Agents (adverse effects, therapeutic use)
• Primary Myelofibrosis (drug therapy)
• Thalidomide (adverse effects, therapeutic use)
• Treatment Outcome